Phase II Open Label Single Arm Exploratory Trial of Oral Afatinib Monotherapy Following Platinum Failure for Patients With Advanced/Metastatic Urothelial Tract Carcinoma With ERBB Receptor Deregulation.

Trial Profile

Phase II Open Label Single Arm Exploratory Trial of Oral Afatinib Monotherapy Following Platinum Failure for Patients With Advanced/Metastatic Urothelial Tract Carcinoma With ERBB Receptor Deregulation.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Dec 2017

At a glance

  • Drugs Afatinib (Primary)
  • Indications Urogenital cancer
  • Focus Therapeutic Use
  • Acronyms LUX-Bladder 1
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 12 Sep 2017 According to a trial design presented at the 42nd European Society for Medical Oncology Congress, recruitment is ongoing in Spain and planned in two additional European countries.
    • 12 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.
    • 14 Feb 2017 Planned End Date changed from 1 Oct 2018 to 1 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top